Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder

References

• Chapple CR. Introduction and conclusions. Improving the management of lower urinary tract symptoms in real life practices. Eur Urol 2001;39(3 Suppl):1-5
   Google Scholar
• Abdel-Aziz KF, Lemack GE. Overactive bladder in the male patient: bladder, outlet, or both? Curr Urol Rep 2002;3:445-51
   Google Scholar
• Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006;49:651-9
   PubMed Web of Science ®Google Scholar
• Verhamme KM, Dieleman JP, Bleumink GS, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care–the Triumph project. Eur Urol 2002;42:323-8
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6
   PubMed Web of Science ®Google Scholar
• Irwin DE, Mungapen L, Milsom I, et al. The economic impact of overactive bladder syndrome in six Western countries. BJU Int 2009;103:202-9
   PubMed Web of Science ®Google Scholar
• van Exel NJ, Koopmanschap MA, McDonnell J, et al. Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six European countries: report of the TRIUMPH study. Eur Urol 2006;49:92-102
   PubMed Web of Science ®Google Scholar
• Polder JJ, Meerding WJ, Koopmanschap MA, et al. [The cost of sickness in the Netherlands in 1994; the main determinants were advanced age and disabling conditions]. Ned Tijdschr Geneeskd 1998;142:1607-11
   Google Scholar
• Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296:2319-28
   PubMed Web of Science ®Google Scholar
• Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005;174:1334-8
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim HW, Lee SJ, et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004;94:817-20
   PubMed Web of Science ®Google Scholar
• Athanasopoulos A, Perimenis P. Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction. Expert Opin Pharmacother 2005;6:2429-33
   PubMed Web of Science ®Google Scholar
• de la Rosette J, Alivizatos G, Madersbacher S, et al. Guidelines on Benign Prostatic Hyperplasia. Arnhem: European Association of Urology, 2009
   Google Scholar
• AUA BPH Guideline Update Panel. AUA guideline on the management of benign prostatic hyperplasia: diagnosis and treatment recommendations. Linthicum: AUA Guideline on the Management of Benign Prostatic Hyperplasia (BPH), 2003
   Google Scholar
• Tkocz M, Prajsner A. Comparison of long-term results of transurethral incision of the prostate with transurethral resection of the prostate, in patients with benign prostatic hypertrophy. Neurourol Urodyn 2002;21:112-6
   Web of Science ®Google Scholar
• Mattiasson A, Wagrell L, Schelin S, et al. Five-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. Urology 2007;69:91-6; discussion 6–7
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009;104:352-60
   PubMed Web of Science ®Google Scholar
• Ware J, Jr Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108
   PubMed Web of Science ®Google Scholar
• Gray AM, Rivero-Arias O, Clarke PM. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making 2006;26:18-29
   PubMed Web of Science ®Google Scholar
• British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. http://bnf.org/bnf/index.htm. Accessed January 2010
   Google Scholar
• UK Office for National Statistics. Consumer price index figures. http://www.statistics.gov.uk/statbase/tsdataset.asp?vlnk=7174&More=Y. Accessed January 2010
   Google Scholar
• Department of Health. National Health Service Reference Costs 2008-2009. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_111591. Accessed January 2010
   Google Scholar
• Speakman M, Khullar V, Mundy A, et al. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin 2008;24:2173-9
   PubMed Web of Science ®Google Scholar
• Hakkaart L, Verboom P, Phillips R, et al. The cost utility of solifenacin in the treatment of overactive bladder. Int Urol Nephrol 2009;41:293-8
   PubMed Web of Science ®Google Scholar
• McDonnell J, Busschbach JJ, Kok E, et al. Lower urinary tract symptoms suggestive of benign prostatic obstruction–Triumph: health-economical analysis. Eur Urol 2001;39(3 Suppl):37-41
   Google Scholar
• DiSantostefano RL, Biddle AK, Lavelle JP. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. BJU Int 2006;97:1007-16
   PubMed Web of Science ®Google Scholar
• DiSantostefano RL, Biddle AK, Lavelle JP. The long-term cost effectiveness of treatments for benign prostatic hyperplasia. Pharmacoeconomics 2006;24:171-91
   Google Scholar